News | July 06, 2023
Croda completes acquisition of Solus Biotech
This acquisition will significantly strengthen Croda’s Beauty Actives portfolio and increases its exposure to targeted prestige segments
This acquisition will significantly strengthen Croda’s Beauty Actives portfolio and increases its exposure to targeted prestige segments
Construction will begin this year with the new capacity anticipated by 2025
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
According to GlobalData’s analyst consensus forecast, OTX-2002 is projected to have the highest revenue by 2028, with sales of $1.6 billion during that year
Kyfora Bio will focus on the synthesis of cationic polymers, lipids, and other materials used in nucleic acid delivery for cell and gene therapies.
This new €59 million, 70,000 square foot facility, officially opened today, brings 50 new jobs to the area
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
Moderna continues to expand its mRNA platform for a range of additional clinical applications and routes of administration including a modality for lung delivery
Both companies have been selected for stand-by production by German government
The investment will significantly enhance the development of high-purity lipid systems, essential delivery systems for next generation nucleic acid drugs such as mRNA vaccines
Subscribe To Our Newsletter & Stay Updated
